What top creators are saying about Hims & Hers Health, Inc.(HIMS)

Positioned as the clear winner-take-most leader in the telehealth and digital pharmacy space with high projected forward revenue growth and massive scale advantages.

Working through a correction phase that may be nearing its end, with upcoming news announcements regarding peptides suggesting potential re-engagement opportunities.

Acquired a peptide compounding facility and positioned itself for the peptide market, acting as a speculative play on telehealth.

Experienced a price drop due to an FTC lawsuit, but legal proceedings will take years while business catalysts like GLP-1s and international growth remain robust.

Sold off sharply to the $27-$29 range, viewed as an irrational reaction since healthcare subscription services are recession-resistant with strong recurring revenue.

Maintains a strong medium-term trend and is considered a high-beta growth play tied to consumer trends in peptides and alternative health treatments.

Dropped significantly due to disappointment and market skepticism regarding its peptide business expansion.

Increasingly trading based on peptide regulation news and FDA announcements rather than traditional telemedicine fundamentals.

The stock is considered undervalued at 3x gross profit despite 35% revenue growth and a 50% market share in U.S. telehealth. Current 'Peptide FUD' and analyst downgrades are viewed as a temporary mispricing of a high-growth disruptor.

Chart printing a bullish fractal; linked to the growing consumer biotech theme.

Noted as a successful play within the peptide and telehealth space.

Very undervalued; analyst recommends using macro-driven dips as a buying opportunity.

Identified as a hyper-growth stock currently being punished by market sentiment despite consistent revenue growth and improving fundamentals.

Reached a 6-month high of $37 following a successful analyst call at $18.

Experienced a 4X gain followed by a crash to previous lows; serves as a warning of high-growth stock volatility.

Showing resilience and growth, benefiting from a broader biotech and healthcare bid.

Lacks the scale to defend its intellectual property against giants like Eli Lilly.

Aggressively capturing demand for GLP-1 weight loss medications like Wegovy.

Viewed as very cheap despite a recovery from previous massive drawdowns; cited as a high-growth asset requiring patience.

Used as a case study for contrarian investing; stock has doubled recently despite previous negative social media sentiment.

Positioned as a leader in the GLP-1 market with a high-growth subscription model that bypasses insurance friction; viewed as undervalued with significant upside from international expansion and new peptide products.

Expanding into the high-demand GLP-1 weight loss market with offerings like Wegovy.

Market is ignoring growth from GLP-1 medications and the Eucalyptus acquisition; trading at an irrational discount despite pristine fundamentals.

Faces competitive threats from new influencer-led distribution brands like Longevity Rx.

Identified as undervalued based on fundamental analysis, though short-term price action remains irrational.

Bullishness driven by GLP-1 weight loss drug approvals and peptide trends.

Experiencing nonsensical 10% intraday swings without substantive news, reflecting current market volatility.

Suggested as a secondary 'basket' play to gain exposure to the GLP-1 trend through its oral solution offerings.

Price movement tracked at $28.01

The speaker views the 10% sell-off as nonsensical, comparing their products to inelastic staples with subscription-based demand that should resist economic downturns.

Aggressively expanding into the longevity market with a 90% recurring revenue model and high margins; viewed as a long-term hold that is currently undervalued despite heavy short interest.

Identified as a key player in the weight loss and telehealth space despite earnings volatility.

Showing resilience and technical strength moving toward the $30 price level.

Identified as an undervalued fintech/disruptor sector company ignored by the traditional financial establishment.

Strategic acquisition of Eucalyptus and strong subscriber growth drive a bullish outlook; analyst considers the stock 'dirt cheap' with a 'Rule of 40' score of 49.

Described as 'dirt cheap' with strong ARR growth from the Eucalyptus acquisition; preferred long-term buy while market ignores fundamentals.

Significant $1.2 million insider buy, high gross margins (74%), and deep value valuation (0.1 EV/GP/RG) compared to AI momentum stocks.

Insider buys reported.

Primary beneficiary of a medical breakthrough in hair loss treatment.

Successful trade based on peptide expert thesis; speaker is a power user.

Bullish on personalized medicine; chart shows an inverse head and shoulders breakout pattern.

Beneficiary of the peptides (GLP-1) market; the recent dip is viewed as a base-building exercise before an explosive move.

The market overreacted to a 0% interest convertible debt offering; the company is using funds for high-growth AI integration and the Eucalyptus acquisition, creating a 'buy the dip' opportunity.

Taking advantage of high stock prices to raise capital, leading to dilution concerns.

Recent loser in portfolio following poor earnings report; highlights volatility in mid-cap growth.

Currently being researched as a potential candidate for the next wave of the peptide/weight loss trend.

Financials are slowing and chart looks poor; avoid until it hits the $17-$20 range.

Benefit from the 'peptide explosion' and high social demand for weight loss treatments.

The stock dropped 20% despite increasing guidance, creating a potential divergence in value compared to the overheated AI sector.

Noted for a brutal 14% drop in price.